Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors, antagonists |
Mechanism GSDME inhibitors(gasdermin E inhibitors), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC20H23ClFNO |
InChIKeyGGUSQTSTQSHJAH-UHFFFAOYSA-N |
CAS Registry119431-25-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Preclinical | China | 04 Nov 2024 | |
Amyotrophic Lateral Sclerosis | Discovery | France | - | |
Brain Injuries | Discovery | - | - | |
Craniocerebral Trauma | Discovery | United States | - | - |
Craniocerebral Trauma | Discovery | European Union | - | - |
Multiple Sclerosis | Discovery | France | - | |
Stroke | Discovery | - | - |